Femasys Inc. is a biomedical company specializing in innovative solutions for women’s reproductive health. The company focuses on minimally invasive, non-surgical technologies designed to be administered in the physician’s office, aiming to improve patient experience and streamline care pathways. Its current portfolio centers on infertility treatment, diagnostic imaging, and gynecologic interventions. Key products include FemaSeed Intratubal Insemination, an infertility treatment intended to deliver sperm directly into the fallopian tube, and FemVue, a companion diagnostic that enables ultrasound-based assessment of the fallopian tubes. Femasys Inc. also offers FemCerv, a device for cervical tissue sampling to support cervical cancer diagnosis, along with FemCath and FemChec for fallopian tube evaluation. In addition, the company is developing FemBloc as a non-surgical option for permanent birth control. Headquartered in the United States, Femasys Inc. serves healthcare providers in domestic and international markets, addressing significantly underserved areas within women’s healthcare.